YOTI
GeneMe , a leading biotech company based in Gdańsk, Poland has developed “FRANKD” – a fast, scalable and reliable mouth swab test for COVID-19 that is completed on-premises in on average 13-25 minutes with no laboratory involvement. The GeneMe FRANKD test has been independently validated with 100% Sensitivity and 100% Specificity by Gdańsk University of Technology.
FRANKD requires less time to produce a result than the gold-standard RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) reference test recommended by the World Health Organization. With consent, results are automatically issued on to each individual’s secure, free Yoti digital ID app . The test will cost businesses in the region of £10, making it cost-effective to perform mass daily testing and point-of-entry testing at care homes, airports, offices and many other locations.
Dawid Nidzworski Founder and CEO of GeneMe and developer of FRANKD said:
“We are extremely pleased with the quality of the FRANKD test and the contribution it will make towards the fight against the coronavirus pandemic and its damaging effects on public health and society
”.
FRANKD is currently in talks with governments and businesses across Europe to roll out millions of tests over the coming months, enabling key industries to test hundreds of thousands of employees daily, to help understand the spread of the virus and to monitor the infection R factor more accurately.
The test uses a patented enzyme rather than the currently scarce reagents used in RT-PCR tests to rapidly produce a definitive and reliable result. FRANKD is therefore scalable with 5m monthly tests expected from August. Use of a portable machine analyser to amplify the virus within the sample ensures high test accuracy. During June and July, FRANKD tests will be processed using hundreds of existing analyser machines, able to handle 90 tests every 30 minutes, but GeneMe expects affordable bespoke machines to be available from August.
What differentiates FRANKD from other viral testing solutions is that it is suitable for mass testing; 90 people can be tested at a time, every 30 minutes with one device, massively reducing the cost of testing. Testing on-premises by trained staff removes delays and the challenge of getting test samples to lab technicians to process. Independent validation of the FRANKD test is underway and European CE regulatory certification is expected by early June.
Testing care workers daily could dramatically reduce the spread of infection within the care home sector and beyond. Testing passengers prior to passing through airport security could also prevent disease spread during passenger air travel, reducing the need for mass quarantine. Testing all hotel guests and employees daily could allow hotels to reopen at significantly lower risk. A specific web application from Yoti will ensure all 90 tests within a batch are uniquely assigned to the correct owner before entering the analyser machine.
Individuals use the secure, free Yoti digital ID app to link themselves to their test and, with consent, the digital test result is automatically added into the tested person’s Yoti. Organisations including the NHS already securely issue digital ID cards using the Yoti app credential management platform. Individuals can present or share their tamperproof, verified details with other parties in seconds - including their test result - whether in person or online, with a tap of a button or scan of a QR code.
Anti-fraud measures are built into Yoti’s reusable digital ID, critically offering much higher trust than is possible with traditional paper and plastic-based identity documents or paper health certificates. Audit receipts are issued securely to both the individual and the recipient individual or organisation when results are shared remotely. The Yoti app is currently available in English, with French, Spanish, Polish and German to be released shortly, followed by further languages.
Kasjan Szemiako
- CTO of GeneMe and developer of FRANKD said:
“We chose Yoti because of its security, user interface and reputation. We will share the results of the test directly with Yoti to ensure data privacy and enable user control
.”
Robin Tombs
- Yoti Co-Founder and CEO said:
“We’re delighted FRANKD has chosen Yoti to enable individuals to manage their COVID-19 test results securely on their phone. Getting the world of business and sport back up and running safely during this coronavirus pandemic is so important. Get FRANKD with Yoti.”
===ENDS===
About FRANKD
Contact colin@nexd.partners or visit www.geneme.eu
GeneMe develops, registers and produces diagnostic kits for the detection of SARS-CoV-2 and over 240 other pathogens. All kits are based on direct virus RNA detection in a sample.
GeneMe uses a special patented enzyme for virus detection.
Test results were validated by the Gdańsk University of Technology.
Test Sensitivity results show that the average detection time for a sample containing 1 million viral copies was 12 minutes 45 seconds, and for 10 viral copies was 23 minutes 25 seconds. A German study has reported that an COVID-19 infected individual has an average of 670,000 viral copies per swab during the first 5 days of their illness. https://www.medrxiv.org/content/medrxiv/early/2020/03/08/2020.03.05.20030502.full.pdf
The GeneMe FRANKD test requires less time to produce a result than the gold-standard RT-PCR reference test recommended by the World Health Organization.
Test Specificity results show that no false positives were obtained when testing against 4 other coronaviruses.
FRANKD - stands for Fast, Reliable, Accurate, No laboratory and available in a Kit form to be used on-premises Daily.
Dawid Nidzworski one of the Co-founder’s of GeneMe is also the creator of the Institute of Biotechnology and Molecular Medicine (IBMM).
The Institute of Biotechnology and Molecular Medicine (IBMM) is an independent, elite, biomedical research institution. The thematic scope of IBMM activities includes, among others, biotechnology, medicine, diagnostics, molecular biology and material engineering.
More on www.ibmm.pl
About Yoti
Contact Covid19@yoti.com or visit www.yoti.com .
Yoti is a digital ID and credential management platform that allows organisations to verify identities and trusted credentials online and in person. Yoti’s products span identity verification, age assurance, document e-signing, access management and biometric authentication.
Yoti is certified to ISO/IEC 27001:2013 for ID Verification Services. Yoti is ISAE 3000 (SOC 2), Type 2 certified for its technical and organisational security processes and is a Secured by Design (Official Police Security Initiative) member company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200515005230/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Announces Industry First 5G-Advanced 3GPP R18 Automotive-Grade Cellular Module, Delivering Unmatched Performance and Reliability2.1.2026 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the world's first 5G-advanced (5G-A) automotive-grade cellular module, the AR588MA, establishing it as the industry's highest-performing and most reliable wireless communication product for vehicles. Based on MediaTek's latest-generation MT2739 platform, the AR588MA supports 5G-A communication technology and is the world's first to comply with the 3GPP R18 standard protocol. The module also features both NB-NTN and NR-NTN satellite communication capabilities, supports Dual SIM Dual Active (DSDA) technology, offering improved stability and reliability on cellular connections and includes intelligent driving scenario recognition. Designed in compliance with the AEC-Q104 Grade 2 automotive standard, it delivers faster, more stable connectivity and reliable security for in-vehicle communication and benefiting the on-roof applications like smart antenna for automotive with higher temperatu
Interactive Brokers’ Individual and Hedge Fund Clients Outperformed the S&P 500 on Average in 20252.1.2026 16:00:00 CET | Press release
Lower costs, global market access, and efficient execution contributed to stronger client outcomes. Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that its clients outperformed the S&P 500 Index in 2025, reflecting the benefits of cost efficiency, execution quality, and broad access to global markets. In 2025, Interactive Brokers’ individual clients achieved an average return of 19.20%, compared with the 17.9% return of the S&P 500 Index. During the same period, Interactive Brokers’ hedge fund clients achieved an average return of 28.91%, outperforming the index by approximately 11 percentage points. These results demonstrate how Interactive Brokers helps enhance client returns across the investment lifecycle. Global market access enables clients to allocate capital across various regions and asset classes, while lower trading and financing costs, along with efficient execution, help IBKR investors retain more of their returns over time. “Inv
Aeromexico Repeats as Most On-Time Global Airline; Qatar Airways Claims Platinum Award2.1.2026 11:00:00 CET | Press release
Virgin Atlantic wins new award as most improved airline for on-time performance Aeromexico maintained a 90.02% on-time performance to claim the world's most on-time global airline title for the second consecutive year, according to Cirium's 2025 On-Time Performance Review released today. The Mexican carrier becomes only the second airline to achieve consecutive global wins since Cirium launched the program in 2009, operating 188,859 flights across 23 countries while maintaining industry-leading schedule reliability. Aeromexico Holds Global Lead; Regional Champions Crowned Aeromexico secured the global airline title with 90.02% on-time performance, holding off strong competition from Saudia in second place with 86.53% and SAS with 86.09% in third. The margin between first and third place was 3.93 percentage points, reflecting the strong performance of Aeromexico in 2025. Regional winners included: North America: Delta Air Lines won for the fifth consecutive year with 80.90% on-time perf
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 08:00:00 CET | Press release
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026 Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizuma
Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 15:00:00 CET | Press release
The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
